Literature DB >> 27037752

Emerging Roles of Epigenetic Regulator Sin3 in Cancer.

N Bansal1, G David2, E Farias1, S Waxman3.   

Abstract

Revolutionizing treatment strategies is an urgent clinical need in the fight against cancer. Recently the scientific community has recognized chromatin-associated proteins as promising therapeutic candidates. However, there is a need to develop more targeted epigenetic inhibitors with less toxicity. Sin3 family is one such target which consists of evolutionary conserved proteins with two paralogues Sin3A and Sin3B. Sin3A/B are global transcription regulators that provide a versatile platform for diverse chromatin-modifying activities. Sin3 proteins regulate key cellular functions that include cell cycle, proliferation, and differentiation, and have recently been implicated in cancer pathogenesis. In this chapter, we summarize the key concepts of Sin3 biology and elaborate the recent advancements in the role of Sin3 proteins in cancer with specific examples in multiple endocrine neoplasia type 2, pancreatic ductal adenocarcinoma, and triple negative breast cancer. Finally, a program to create an integrative approach for screening antitumor agents that target chromatin-associated factors like Sin3 is presented.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Epigenetics; HDAC; Multiple endocrine neoplasia type 2; Pancreatic ductal adenocarcinoma; Sin3A; Sin3B; Triple negative breast cancer

Mesh:

Substances:

Year:  2016        PMID: 27037752     DOI: 10.1016/bs.acr.2016.01.006

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  27 in total

1.  Haploinsufficiency of MeCP2-interacting transcriptional co-repressor SIN3A causes mild intellectual disability by affecting the development of cortical integrity.

Authors:  Josefine S Witteveen; Marjolein H Willemsen; Thaís C D Dombroski; Nick H M van Bakel; Willy M Nillesen; Josephus A van Hulten; Eric J R Jansen; Dave Verkaik; Hermine E Veenstra-Knol; Conny M A van Ravenswaaij-Arts; Jolien S Klein Wassink-Ruiter; Marie Vincent; Albert David; Cedric Le Caignec; Jolanda Schieving; Christian Gilissen; Nicola Foulds; Patrick Rump; Tim Strom; Kirsten Cremer; Alexander M Zink; Hartmut Engels; Sonja A de Munnik; Jasper E Visser; Han G Brunner; Gerard J M Martens; Rolph Pfundt; Tjitske Kleefstra; Sharon M Kolk
Journal:  Nat Genet       Date:  2016-07-11       Impact factor: 38.330

2.  A complex interplay between SAM synthetase and the epigenetic regulator SIN3 controls metabolism and transcription.

Authors:  Mengying Liu; Nirmalya Saha; Ambikai Gajan; Nadia Saadat; Smiti V Gupta; Lori A Pile
Journal:  J Biol Chem       Date:  2019-11-27       Impact factor: 5.157

3.  A Structured Workflow for Mapping Human Sin3 Histone Deacetylase Complex Interactions Using Halo-MudPIT Affinity-Purification Mass Spectrometry.

Authors:  Charles A S Banks; Janet L Thornton; Cassandra G Eubanks; Mark K Adams; Sayem Miah; Gina Boanca; Xingyu Liu; Maria L Katt; Tari J Parmely; Laurence Florens; Michael P Washburn
Journal:  Mol Cell Proteomics       Date:  2018-03-29       Impact factor: 5.911

4.  Coregulator Sin3a Promotes Postnatal Murine β-Cell Fitness by Regulating Genes in Ca2+ Homeostasis, Cell Survival, Vesicle Biosynthesis, Glucose Metabolism, and Stress Response.

Authors:  Xiaodun Yang; Sarah M Graff; Cody N Heiser; Kung-Hsien Ho; Bob Chen; Alan J Simmons; Austin N Southard-Smith; Gregory David; David A Jacobson; Irina Kaverina; Christopher V E Wright; Ken S Lau; Guoqiang Gu
Journal:  Diabetes       Date:  2020-04-03       Impact factor: 9.461

Review 5.  Non-mammalian models of multiple endocrine neoplasia type 2.

Authors:  Tirtha K Das; Ross L Cagan
Journal:  Endocr Relat Cancer       Date:  2018-02       Impact factor: 5.678

6.  Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo.

Authors:  Jian Chen; Xiaofei Huang; Cheng Tao; Li Wang; Zide Chen; Xinping Li; Qiang Zeng; Min Ma; Ren Zhang; Zhengzhi Wu
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-30       Impact factor: 3.333

7.  Difference of binding modes among three ligands to a receptor mSin3B corresponding to their inhibitory activities.

Authors:  Tomonori Hayami; Narutoshi Kamiya; Kota Kasahara; Takeshi Kawabata; Jun-Ichi Kurita; Yoshifumi Fukunishi; Yoshifumi Nishimura; Haruki Nakamura; Junichi Higo
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

8.  Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension.

Authors:  Malik Bisserier; Prabhu Mathiyalagan; Shihong Zhang; Firas Elmastour; Peter Dorfmüller; Marc Humbert; Gregory David; Sima Tarzami; Thomas Weber; Frederic Perros; Yassine Sassi; Susmita Sahoo; Lahouaria Hadri
Journal:  Circulation       Date:  2021-06-03       Impact factor: 39.918

9.  Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer.

Authors:  Nidhi Bansal; Almudena Bosch; Boris Leibovitch; Lutecia Pereira; Elena Cubedo; Jianshi Yu; Keely Pierzchalski; Jace W Jones; Melissa Fishel; Maureen Kane; Arthur Zelent; Samuel Waxman; Eduardo Farias
Journal:  Oncotarget       Date:  2016-07-12

10.  Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression.

Authors:  Wen-Bin Tsai; Yan Long; Jeffrey T Chang; Niramol Savaraj; Lynn G Feun; Manfred Jung; Helen H W Chen; Macus Tien Kuo
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.